Jenette Creaney

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6889329/publications.pdf

Version: 2024-02-01

90 papers	4,660 citations	147801 31 h-index	102487 66 g-index
93 all docs	93 docs citations	93 times ranked	4537 citing authors

#	Article	IF	Citations
1	The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genetics, 2011, 43, 668-672.	21.4	617
2	Mesothelin-family proteins and diagnosis of mesothelioma. Lancet, The, 2003, 362, 1612-1616.	13.7	516
3	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	9.4	422
4	Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 1541-1549.	1.6	199
5	Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax, 2014, 69, 895-902.	5.6	128
6	A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. Journal of Thoracic Oncology, 2016, 11, 573-582.	1.1	126
7	Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012, 7, 1184-1191.	1.1	115
8	Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. Journal of Thoracic Oncology, 2008, 3, 851-857.	1.1	109
9	Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax, 2007, 62, 569-576.	5.6	106
10	Soluble Mesothelin-related Protein in an Asbestos-exposed Population. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 832-837.	5.6	105
11	Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden. Clinical Cancer Research, 2011, 17, 1181-1189.	7.0	101
12	A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology, 2013, 45, 44-48.	0.6	97
13	The Bloom's Syndrome Protein (BLM) Interacts with MLH1 but Is Not Required for DNA Mismatch Repair. Journal of Biological Chemistry, 2001, 276, 30031-30035.	3.4	91
14	A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012, 7, 1449-1456.	1.1	89
15	Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. Scientific Reports, 2016, 6, 32643.	3.3	85
16	Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma. Chest, 2007, 132, 1239-1246.	0.8	79
17	Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2238-2246.	2.5	72
18	Malignant Mesothelioma Biomarkers. Chest, 2017, 152, 143-149.	0.8	72

#	Article	IF	Citations
19	Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study. PLoS ONE, 2013, 8, e61253.	2.5	71
20	Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma. Acta Cytologica, 2015, 59, 2-16.	1.3	71
21	Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer, 2013, 82, 491-498.	2.0	61
22	Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. PLoS ONE, 2018, 13, e0190264.	2.5	57
23	Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. CytoJournal, 2015, 12, 26.	1.7	57
24	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 2013, 81, 422-427.	2.0	51
25	The BLM helicase is necessary for normal DNA double-strand break repair. Cancer Research, 2002, 62, 2766-70.	0.9	50
26	Serum and pleural fluid biomarkers for mesothelioma. Current Opinion in Pulmonary Medicine, 2009, 15, 366-370.	2.6	48
27	Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesotheliomaâ€"Which is best?. Lung Cancer, 2011, 74, 55-60.	2.0	48
28	A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions. Clinical Cancer Research, 2006, 12, 5129-5135.	7.0	46
29	A genome-wide association study for malignant mesothelioma risk. Lung Cancer, 2013, 82, 1-8.	2.0	45
30	Guidelines for the cytopathologic diagnosis of epithelioid and mixedâ€type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Diagnostic Cytopathology, 2015, 43, 563-576.	1.0	34
31	Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer, 2017, 17, 386.	2.6	34
32	A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. Cancer Genomics and Proteomics, 2017, 14, 103-118.	2.0	34
33	Transient Treg depletion enhances therapeutic antiâ€cancer vaccination. Immunity, Inflammation and Disease, 2017, 5, 16-28.	2.7	33
34	Detection of Malignant Mesothelioma in Asbestos-Exposed Individuals: The Potential Role of Soluble Mesothelin-Related Protein. Hematology/Oncology Clinics of North America, 2005, 19, 1025-1040.	2.2	31
35	Comparison of the Diagnostic Accuracy of theMSLNGene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum. Disease Markers, 2013, 35, 119-127.	1.3	31
36	Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer, 2017, 17, 396.	2.6	30

#	Article	IF	Citations
37	Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	30
38	Mesothelin and kidney functionâ€"Analysis of relationship and implications for mesothelioma screening. Lung Cancer, 2011, 73, 320-324.	2.0	27
39	Discovery of new biomarkers for malignant mesothelioma. Current Pulmonology Reports, 2015, 4, 15-21.	1.3	27
40	Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene, 2015, 563, 103-105.	2.2	27
41	Malignant pleural fluid from mesothelioma has potent biological activities. Respirology, 2017, 22, 192-199.	2.3	27
42	Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clinical Chemistry and Laboratory Medicine, 2010, 48, 869-74.	2.3	26
43	Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Current Opinion in Pulmonary Medicine, 2015, 21, 352-356.	2.6	26
44	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. OncoImmunology, 2015, 4, e1011492.	4.6	26
45	Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. Chest, 2016, 149, 1494-1500.	0.8	25
46	Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis. Oncotarget, 2015, 6, 1519-1530.	1.8	25
47	Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma. Disease Markers, 2014, 2014, 1-10.	1.3	24
48	Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Medicine, 2022, 14, .	8.2	24
49	Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer, 2018, 119, 64-70.	2.0	23
50	BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. Journal of Thoracic Oncology, 2022, 17, 921-930.	1.1	23
51	A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. Lung Cancer, 2020, 140, 87-92.	2.0	21
52	ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4â€"10Âyears in advance of clinical symptoms. Clinical Proteomics, 2016, 13, 2.	2.1	20
53	MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions. Disease Markers, 2019, 2019, 1-9.	1.3	20
54	The Current Lung Cancer Neoantigen Landscape and Implications for Therapy. Journal of Thoracic Oncology, 2021, 16, 922-932.	1.1	19

#	Article	IF	Citations
55	Immunotherapy for Lung Malignancies. Chest, 2017, 151, 891-897.	0.8	17
56	Auto-Antibodies to Î²-F1-ATPase and Vimentin in Malignant Mesothelioma. PLoS ONE, 2011, 6, e26515.	2.5	16
57	Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. BMJ Open, 2016, 6, e011480.	1.9	16
58	Sensitivity of Urinary Mesothelin in Patients with Malignant Mesothelioma. Journal of Thoracic Oncology, 2010, 5, 1461-1466.	1.1	15
59	Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. Cancer Immunology, Immunotherapy, 2021, 70, 3249-3258.	4.2	14
60	Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. BMC Cancer, 2015, 15, 983.	2.6	13
61	Immunotherapy strategies for mesothelioma â€“ the role of tumor specific neoantigens in a new era of precision medicine. Expert Review of Respiratory Medicine, 2019, 13, 181-192.	2.5	13
62	Advances in pathological diagnosis of mesothelioma. Current Opinion in Pulmonary Medicine, 2019, 25, 354-361.	2.6	12
63	Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. OncoImmunology, 2020, 9, 1684713.	4.6	12
64	Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. OncoImmunology, 2020, 9, 1684714.	4.6	12
65	Association of Biomarker Levels with Severity of Asbestos-Related Diseases. Safety and Health at Work, 2012, 3, 17-21.	0.6	10
66	Bacterial Infection Elicits Heat Shock Protein 72 Release from Pleural Mesothelial Cells. PLoS ONE, 2013, 8, e63873.	2.5	10
67	Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions. Respiration, 2019, 98, 48-54.	2.6	9
68	Autoimmune antibodies and asbestos exposure: Evidence from Wittenoom, Western Australia. American Journal of Industrial Medicine, 2018, 61, 615-620.	2.1	8
69	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Research Notes, 2018, 11, 864.	1.4	7
70	Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1â€3 tyrosine kinase inhibitor anticancer therapy. Clinical and Experimental Ophthalmology, 2021, 49, 579-590.	2.6	7
71	Soluble mesothelin related protein in mesothelioma. Journal of Thoracic Oncology, 2006, 1, 172-4.	1.1	7
72	Whatâ€™s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. OncoImmunology, 2022, 11, 2038403.	4.6	7

#	Article	IF	Citations
73	Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1973-1982.	2.5	6
74	Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?. Lung Cancer, 2013, 80, 39-44.	2.0	5
75	Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. Biomarkers, 2016, 21, 551-561.	1.9	5
76	Malignant Pleural Mesothelioma: an Update for Pulmonologists. Current Pulmonology Reports, 2019, 8, 40-49.	1.3	4
77	Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol. BMJ Open Respiratory Research, 2020, 7, e000551.	3.0	4
78	Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. PLoS ONE, 2021, 16, e0250628.	2.5	4
79	Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology. Cytopathology, 2022, 33, 84-92.	0.7	4
80	The continual search for ideal biomarkers for mesothelioma: the hurdles. Journal of Thoracic Disease, 2013, 5, 364-6.	1.4	4
81	How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies. Frontiers in Pharmacology, 2022, 13, 858557.	3.5	4
82	Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies. Annals of the American Thoracic Society, 2016, 13, 1003-1004.	3.2	3
83	Histologically Diverse BAP1-Deficient Melanocytic Tumors in a Patient With BAP1 Tumor Predisposition Syndrome. American Journal of Dermatopathology, 2020, 42, 872-875.	0.6	3
84	Hyaluronic acid in viscous malignant mesothelioma pleural effusion. Respirology Case Reports, 2021, 9, e00694.	0.6	3
85	Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology. Cancer Cytopathology, 2022, , .	2.4	3
86	A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Review of Anticancer Therapy, 2021, 21, 465-474.	2.4	1
87	Autoantibodies and cancer among asbestos-exposed cohorts in Western Australia. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2021, 84, 475-483.	2.3	1
88	Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax, 2015, 70, 374-375.	5.6	0
89	BAP1 mutations in mesothelioma: advances and controversies. Current Pulmonology Reports, 2016, 5, 13-19.	1.3	0
90	Endomicroscopy of the pleura highlights challenges and limitations of pleuroscopy. Respirology, 2021, 26, 138-139.	2.3	0